ICO.ST

Iconovo AB (publ) [ICO.ST] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ICO.ST Stock Summary

Top 10 Correlated ETFs

ICO.ST

Top 10 Correlated Stocks

ICO.ST

In the News

ICO.ST Financial details

Company Rating
-
Market Cap
95.69M
Income
-46.12M
Revenue
7.08M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
30
Optionable
No
Shortable
Yes
Earnings
26 Apr 2024
P/E
-2.22
Forward P/E
-
PEG
1.13
P/S
22.77
P/B
1.02
P/C
-
P/FCF
-1.89
Quick Ratio
1.39
Current Ratio
1.7
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-4.57
EPS next Y
-
EPS next Q
-
EPS this Y
-22.85%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
22.06%
Revenue last 5Y
-9.62%
Revenue Q/Q
-69.57%
EPS Q/Q
-2.06%
-
-
-
-
SMA20
-33.33%
SMA50
-50%
SMA100
-60%
Inst Own
-
Inst Trans
-
ROA
-39%
ROE
-49%
ROC
-0.42%
Gross Margin
266%
Oper. Margin
-854%
Profit Margin
-895%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.46-42.0
52W High
-96.88%
52W Low
-81.29%
RSI
26
Rel Volume
0.33
Avg Volume
45.64K
Volume
15.19K
Perf Week
-45.64%
Perf Month
-53.21%
Perf Quarter
-74.11%
Perf Half Y
-74.41%
-
-
-
-
Beta
0.622
-
-
Volatility
0.05%, 0.58%
Prev Close
0%
Price
1.31
Change
-2.96%

Something similar

Top by Market Cap
JPM
FXAIX
ABEA.DE
DHR-PB
MSF.DE
Top Correlated ETFs
XBAK.DE
Top Correlated Stocks
SOM.L
RWS.L
QTCOM.HE
0RG5.L
AZUL4.SA
Similar Market Cap
TLF.TO
FNI
LMVYX
PGUCX
MMECX

Company Profile

Healthcare Medical - Devices
  • Volume Average 45.64K
  • Market Capitalization 95.69M
  • Employee 30
  • CEO Mr. Johan Waborg
  • Headquarters Lund,SE
  • IPO Date 2018-04-06
  • Website https://www.iconovo.se

Iconovo AB (publ) develops and licenses inhalation devices in Sweden. It develops ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler, as well as provides customized inhalation solutions. It serves generic companies. The company has an agreement with Immune System Regulation AB for the development of an inhaled covid-19 vaccine in Iconovo's inhaler ICOone; and Respiratorius AB (publ) to develop inhalation product to treat COPD. Iconovo AB (publ) was founded in 2013 and is based in Lund, Sweden.